CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of
investigational RNA interference (RNAi) therapeutics, today announced
that Douglas M. Fambrough, Ph.D., president and chief executive officer,
will participate in an analyst-led fireside chat at the Leerink Partners
6th Annual Global Healthcare Conference on Wednesday,
February 15, 2017, at 10:30 a.m. ET. The conference will be held at the
Lotte New York Palace Hotel in New York City.
A live webcast of the presentation can be accessed on the Investors &
Media section on the Dicerna website at www.dicerna.com.
An archived replay of the webcast will be available on the Company's
website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on
the discovery and development of innovative RNA interference
(RNAi)-based therapeutics for diseases involving the liver, including
rare diseases, chronic liver diseases, cardiovascular diseases, and
viral infectious diseases. The Company is leveraging its proprietary
GalXC™ RNAi technology platform to build a broad pipeline in these core
therapeutic areas, focusing on target genes where connections between
target gene and diseases are well understood and documented. The Company
intends to discover, develop and commercialize novel therapeutics either
on its own or in collaboration with pharmaceutical partners. For more
information, please visit www.dicerna.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170208005240/en/
Rx Communications Group
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media